Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTTXNASDAQ:KDLYNYSE:UPHNASDAQ:VSEE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTTXBetter Therapeutics$0.00$0.00$0.00▼$0.03$10K1.1515,606 shs358 shsKDLYKindly MD$1.88$1.69$0.65▼$5.25$11.34MN/A1.49 million shs42,024 shsUPHUpHealth$0.73$0.25▼$3.19$5.33M0.51121,201 shs348,700 shsVSEEVsee Health$1.21-2.4%$1.22$1.00▼$14.47$4.36MN/A1.14 million shs30,624 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTTXBetter Therapeutics0.00%0.00%-33.33%+100.00%-98.46%KDLYKindly MD+4.44%+5.62%+16.77%+43.51%+187,999,900.00%UPHUpHealth0.00%0.00%0.00%0.00%0.00%VSEEVsee Health0.00%+4.20%+3.33%-26.19%+123,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKDLYKindly MD1.2804 of 5 stars0.05.00.00.03.01.70.0UPHUpHealthN/AN/AN/AN/AN/AN/AN/AN/AVSEEVsee Health1.9106 of 5 stars2.04.00.00.03.30.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTTXBetter Therapeutics 0.00N/AN/AN/AKDLYKindly MD 0.00N/AN/AN/AUPHUpHealth 0.00N/AN/AN/AVSEEVsee Health 4.00Strong Buy$5.00313.22% UpsideCurrent Analyst Ratings BreakdownLatest UPH, KDLY, VSEE, and BTTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/24/2025VSEEVsee HealthMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.002/21/2025VSEEVsee HealthMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTTXBetter TherapeuticsN/AN/AN/AN/AN/AN/AKDLYKindly MD$2.72M4.17N/AN/AN/A∞UPHUpHealth$153.15M0.00N/A0.18$7.05 per share0.00VSEEVsee Health$6.38M0.68N/AN/A($3.40) per share-0.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTTXBetter Therapeutics-$39.76MN/A0.00∞N/AN/AN/AN/A5/1/2025 (Estimated)KDLYKindly MDN/A-$0.66N/A∞N/AN/AN/AN/AN/AUPHUpHealth-$223M-$4.50N/AN/AN/A-49.08%12.33%3.66%N/AVSEEVsee Health-$4.41MN/A0.00∞N/AN/A-182.59%-58.26%N/ALatest UPH, KDLY, VSEE, and BTTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2025Q4 2024KDLYKindly MDN/A-$0.17N/A-$0.17N/A$0.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTTXBetter TherapeuticsN/AN/AN/AN/AN/AKDLYKindly MDN/AN/AN/AN/AN/AUPHUpHealthN/AN/AN/AN/AN/AVSEEVsee HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTTXBetter TherapeuticsN/AN/AN/AKDLYKindly MDN/A5.435.42UPHUpHealthN/A0.130.13VSEEVsee Health0.160.370.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTTXBetter Therapeutics34.00%KDLYKindly MDN/AUPHUpHealth23.35%VSEEVsee Health1.01%Insider OwnershipCompanyInsider OwnershipBTTXBetter Therapeutics51.40%KDLYKindly MD50.50%UPHUpHealth41.27%VSEEVsee Health6.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTTXBetter Therapeutics4049.86 million24.23 millionOptionableKDLYKindly MDN/A6.03 million2.96 millionN/AUPHUpHealth61117.78 million10.44 millionOptionableVSEEVsee HealthN/A3.60 million3.37 millionN/AUPH, KDLY, VSEE, and BTTX HeadlinesRecent News About These CompaniesVSee Health unveils AI-driven telenursing platformApril 18, 2025 | uk.investing.comVSee Unveils Advanced Telenursing Robotics Solution Targeting 3-5% Reduction in Hospital Nursing CostsApril 16, 2025 | finance.yahoo.comVSee Health Highlights: AI-Powered Telehealth Redefining the $787 Billion Digital Healthcare Market Featured Image featured image Admin MessageApril 2, 2025 | markets.businessinsider.comVSee Health Highlights: AI-Powered Telehealth Redefining the $787 Billion Digital Healthcare MarketApril 2, 2025 | prnewswire.comVSee Health issues letter to shareholders updating progressMarch 7, 2025 | markets.businessinsider.comVSee Issues Shareholder Letter Highlighting 2024 Achievements and Strong Growth Outlook for 2025March 6, 2025 | finance.yahoo.comVSee Health wins telehealth contract for mental health servicesMarch 6, 2025 | finance.yahoo.comVSee Health Secures $444K County Government Contract, Expanding Market Reach in Public Sector HealthcareMarch 5, 2025 | finance.yahoo.comVSee Health and LanguageLine Team Up to Boost Telehealth Adoption with Seamless, Scalable Multilingual CareFebruary 25, 2025 | finance.yahoo.comVSee Health and LanguageLine Team Up to Boost Telehealth Adoption with Seamless, Scalable Multilingual CareFebruary 25, 2025 | businesswire.comMaxim Group Initiates Coverage of VSee Health (VSEE) with Buy RecommendationFebruary 25, 2025 | msn.comVSee Health initiated with a Buy at MaximFebruary 24, 2025 | markets.businessinsider.comMaxim starts VSee Health at Buy, sees good momentum in new contractsFebruary 24, 2025 | markets.businessinsider.comVSee Health signs $560,000 contract with oncology networkFebruary 20, 2025 | markets.businessinsider.comAI in Healthcare Sees Explosive Growth: Key Innovations Investors Should WatchFebruary 11, 2025 | baystreet.caVSee Health renews two-year contract worth $2m with IDN hospital systemFebruary 7, 2025 | msn.comVSee Health Secures $2M Contract Renewal for Neurocritical Care Expansion at Leading Hospital SystemFebruary 7, 2025 | finance.yahoo.comVSee Healthl renews $2M two-year contract with IDN hospital systemFebruary 7, 2025 | markets.businessinsider.comVSee Health wins $340K EHR and virtual care contractFebruary 4, 2025 | msn.comVSee Health secures $340K contract to create AI-enabled EHR systemFebruary 4, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUPH, KDLY, VSEE, and BTTX Company DescriptionsBetter Therapeutics NASDAQ:BTTX$0.0002 0.00 (0.00%) As of 04/30/2025 03:16 PM EasternBetter Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.Kindly MD NASDAQ:KDLY$1.88 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.87 -0.01 (-0.32%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kindly MD, Inc. provides healthcare services. Its services include medication management, behavioral healthcare and alternative treatments. The firm offers evaluation and management, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy. The company was founded by Timothy Pickett in December 2019 and is headquartered in Murray, UT.UpHealth NYSE:UPHUpHealth, Inc., together with its subsidiaries, operates as a digital health services company in the Americas, Europe, and Asia. The company operates through three segments Integrated Care Management, Virtual Care Infrastructure, and Services segments. The Integrated Care Management segment offers SyntraNet, an integrated health management platform that enables clinical and community-based care teams to share information, coordinate care, manage utilization, and improve health outcomes for individuals and populations. The Virtual Care Infrastructure segment provides the Martti platform, a digital health infrastructure that enables its partners to implement unique, private-label telehealth strategies customized to their specific needs and markets, including integrated telehealth and language access services. Its platform also offers telemedicine, such as telestroke, teleneurology, and telepsychiatry services. The Services segment offers behavioral health and pharmacy services, as well as operates HelloLyf CX platform for digital dispensary services and HelloLyf HX platform for digital hospital services; and provides diagnostic laboratory testing services. UpHealth, Inc. was founded in 2019 and is headquartered in Delray Beach, Florida.Vsee Health NASDAQ:VSEE$1.21 -0.03 (-2.42%) Closing price 03:52 PM EasternExtended Trading$1.23 +0.02 (+1.98%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VSee Health, Inc. is a no-code or low-code software as a service (SaaS) platform that enables clinicians and enterprises to create their telehealth workflows without programming. It engages in providing timely, quality healthcare to patients regardless of geographical barriers. The company is headquartered in Boca Raton, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
